Regeneron and Sanofi expand their antibody alliance with four new drug candidates, FDA approves Camzyos for adolescents with obstructive hypertrophic cardiomyopathy, and Michael Abrams questions digital health's savings claims to employers.
News|Articles|August 10, 2023
FDA Announces Second Approval of Gavreto
New indication focuses on metastatic rearranged during transfection fusion-positive non-small cell lung cancer.
Advertisement
After previously approving Gavreto (pralsetinib) for non-small cell lung cancer (NSCLC) in late 2020, the FDA has announced an additional approval for metastatic rearranged during transfection (RET) fusion-positive NSCLC. Backed by an FDA-approved test, efficiency was demonstrated in a total of 237 patients with locally advanced or metastatic RET fusion-positive NSCLC. Patients received pralsetinib until disease progression or unacceptable toxicity, according to an FDA press release.
In the same press release, the FDA stated that the recommended pralsetinib dose is 400 mg orally once daily, to be taken on an empty stomach.
Reference: FDA approves pralsetinib for non-small cell lung cancer with RET gene fusions. FDA. August 9, 2023. Accessed August 10, 2023. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pralsetinib-non-small-cell-lung-cancer-ret-gene-fusions
Advertisement
Related to this article
FDA Approves Expanded Indication for Camzyos for Symptomatic Obstructive Hypertrophic Cardiomyopathy
FDA has expanded Camzyos's approval to treat symptomatic obstructive hypertrophic cardiomyopathy in pediatric patients as young as 12.
Regeneron and Sanofi are expanding their two-decade antibody alliance to co-develop four new long-acting immunology antibodies in a deal worth up to $8 billion.
Digital health's point-solution era is giving way to broader platforms, and the cost-savings claims those platforms make to employers often don't hold up to methodological scrutiny.
CORXEL’s Dr. Bo Liang on why efficacy is no longer obesity medicine's biggest gap — and the four unmet needs that define what comes next.
MRD Testing Is Becoming the Most Important Tool in Oncology Drug Development: Q&A with Eric Matthews
MRD testing is transforming oncology trials — compressing timelines, enriching populations, and generating earlier answers.
Novo Nordisk data show real-world weight loss after switching to its oral semaglutide pill, FDA's peptide rulemaking stalls while its enforcement arm targets compounded peptide sellers, and Avi Pardo flags a compliance blind spot in field teams' text messages with doctors.
Dr. Jeremy Levin joins Ken Banta to share why he believes biotech's future demands a new level of leadership and stakeholder education — and why "mission without method" is a wasted effort.
Advertisement
Advertisement
Trending on PharmExec
1
Regeneron and Sanofi Expand Antibody Alliance with Four New Drugs
2
New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report
3
The Next Chapter in Metabolic Drug Development
4
Novo Reports Real-World Data Showing Weight Loss After Switch to Oral Semaglutide Pill
5